Bexicaserin is a small molecule commercialized by Longboard Pharmaceuticals, with a leading Phase II program in Lennox-Gastaut Syndrome. According to Globaldata, it is involved in 12 clinical trials, of which 5 were completed, 2 are ongoing, and 5 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Bexicaserins valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Bexicaserin is expected to reach an annual total of $596 mn by 2036 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bexicaserin Overview
Longboard Pharmaceuticals Overview
Longboard Pharmaceuticals (Longboard) is a clinical-stage biopharmaceutical company that discover and develops novel, transformative medicines for neurological diseases. The companys pipeline program includes LP352, an oral 5-HT2c super agonist targeting dravet syndrome, lennox-gastaut syndrome (LGS), CDKL5 deficiency disorder, tuberous sclerosis complex (TSC), and other epileptic disorders; LP143, a CB2 agonist against amyotrophic lateral sclerosis (ALS) and neuroinflammatory disorders; and LP659, S1P receptor modulator targeting multiple neuroinflammatory disorders. It is also developing medicines for the treatment of central nervous system neuroinflammatory diseases and epileptic encephalopathies. Longboard is headquartered in La Jolla, California, the US
The operating loss of the company was US$44.8 million in FY2022, compared to an operating loss of US$27.8 million in FY2021. The net loss of the company was US$44 million in FY2022, compared to a net loss of US$27.8 million in FY2021.
For a complete picture of Bexicaserins valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.